Skip to content

Evaluating the Efficacy of Platelet-Rich Plasma (PRP) in Day Surgery of Anterior Popliteal Transtibial Tuberosity High Tibial Osteotomy (APTT-HTO) ": An Interventional Clinical Study

Evaluating the Efficacy of Platelet-Rich Plasma (PRP) in Day Surgery of Anterior Popliteal Transtibial Tuberosity High Tibial Osteotomy (APTT-HTO) ": An Interventional Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090198
Enrollment
Unknown
Registered
2024-09-25
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

APTT-HTO Routine rehabilitation group:Routine rehabilitation
APTT-HTO platelet-rich plasma group:Platelet-rich plasma intervention
APTT-HTO day surgery group:Rapid rehabilitation management process
APTT-HTO platelet-rich plasma + day surgery group:Enhanced recovery after surgery management process + intraoperative use of platelet-rich plasma

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Knee osteoarthritis (2) K/L scores are 2-4 (3) Combined with varus or valgus deformity of tibia (4) No local or systemic infection (5) The subject fully understands the content and risks of this experiment (6) Obtain the informed consent of the subject

Exclusion criteria

Exclusion criteria: (1) being over 90 years of age or under 18 years of age, or not having full capacity for civil conduct (2) HIV, hepatitis virus or syphilis virus infection or serological test positive (3) Rheumatoid arthritis or acquired knee deformity (4) Pregnant or lactating women (5) Tumor patients (patients with suspected tumor but not yet diagnosed, patients with confirmed tumor who will undergo surgery or radiotherapy or chemotherapy, patients with proximal tibial bone tumor) (6) Patients with immunodeficiency (including primary immunodeficiency and secondary immunodeficiency) (7) History of intraluminal drug injection three months ago (8) Participants who are currently participating in other clinical trials (9) Other concomitant diseases are not recommended for participants in this study

Design outcomes

Primary

MeasureTime frame
WOMAC score;Healing of osteotomy gap;Preoperative and postoperative changes of patellofemoral joint;

Secondary

MeasureTime frame
Changes of laboratory indexes before and after operation;Meniscal changes;Changes of anterior and posterior cruciate ligaments;

Countries

China

Contacts

Public ContactYe chuan

Affiliated Hospital of Guizhou Medical University

545255355@qq.com+86 139 8482 2777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026